Zonisamide (All indications)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Källén (Zonisamide) (Controls unexposed, NOS) (Indications NOS), 2013 Tomson (Zonisamide), 2018 Meador (Zonisamide) (Controls unexposed, sick), 2020 The NAAED (Controls unexposed, disease free) (Indications NOS), 2022 42.23[0.81; 6.18]49,591230not evaluable Major congenital malformations Källén (Zonisamide) (Controls unexposed, NOS) (Indications NOS), 2013 Tomson (Zonisamide), 2018 Meador (Zonisamide) (Controls unexposed, sick), 2020 The NAAED (Controls unexposed, disease free) (Indications NOS), 2022 42.23[0.81; 6.18]49,591230not evaluable Growth parameters and prematurity Low birth weight (< 2500g) Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2014 12.17[0.91; 5.14]2698not evaluable Preterm (< 37 weeks) Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2014 11.81[0.85; 3.87]3798not evaluable Small for gestational age (weight) Hernández-Díaz (Zonisamide), 2017 11.90[1.20; 3.00]-125not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Meador (Zonisamide) (Controls unexposed, sick), 2020 11.16[0.02; 62.85]-13not evaluable Neuro-developmental disorders Language disorders/delay Meador (Zonisamide) (Controls unexposed, disease free), 2021 10.33[0.10; 1.06]-11not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons